Shao Weihui

All filings by Shao Weihui on record concern Genscript Biotech Corporation, in the capacity of chief executive. Between 30 March 2023 and 2 September 2026, the trades on record add up to 15 filings.

Market trades split into 5 purchases and 10 sales (€2.2M). The totals exclude 7 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2026 alone, the filings show 1 purchase and 3 sales.

On 7 September 2026 came the latest disclosure, an open-market sale for €612k in Genscript Biotech Corporation. The last purchase on record was published on 10 June 2026, which is 137 days ago. Between a trade and the moment it shows up on HKEX, the median delay is 5 days. The shorter that gap, the sooner other investors can see what insiders have done. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by HKEX and describes the past, not future prices; it is not investment advice.